Livagen

Livagen (KEDA tetrapeptide) is distinguished by two exceptional properties: First, it is one of the most extensively studied peptides for direct chromatin remodeling — research has demonstrated its ability to physically decondense heterochromatin in senescent lymphocytes, reactivating genes silenced during aging on chromosomes 1, 9, and 16. Second, it is the most potent enkephalinase inhibitor among Khavinson peptides, with an IC50 of 20 μM (25-fold more potent than Epithalon at 500 μM), providing natural modulation of the endogenous opioid system.

As cells age, increasing portions of their genome become condensed into heterochromatin — a tightly packed form of DNA that silences gene expression. Livagen penetrates into cell nuclei and binds directly to DNA at specific promoter sequences (GCGG and GGGC), physically inducing chromatin decondensation (deheterochromatinization). This converts facultative heterochromatin back to transcriptionally active euchromatin, reactivating genes that were progressively silenced during aging — including ribosomal genes critical for protein synthesis and genes involved in DNA repair and immune function.

Enkephalins are endogenous opioid peptides that regulate pain perception, immune function, and stress responses. They are normally rapidly degraded by enkephalinase enzymes. Livagen inhibits these enzymes at just 20 μM concentration (more potent than established inhibitors like puromycin), prolonging the activity of natural enkephalins. Importantly, Livagen does NOT directly interact with opioid receptors — it works upstream by preserving naturally produced enkephalins, providing a physiological rather than pharmacological modulation of the opioid system.

The safety data for Livagen is extensive by peptide bioregulator standards. Acute toxicity studies showed no observable toxic effects at doses 5,000 times higher than recommended clinical doses. A 266-person clinical study observed patients over 6-8 years with no serious adverse events documented. The most common side effect is mild injection site reaction. No mutagenic, teratogenic, or genotoxic effects have been reported. However, long-term data is primarily from Russian clinical experience, and formal Western regulatory safety assessments have not been conducted.

Livagen has been studied and administered via both injectable (intramuscular and subcutaneous) and oral routes. In Russia, an oral capsule form (0.1 mg daily) is available as the Cytogen Livagen product for 10-30 day courses. Animal studies demonstrated that the KEDA tetrapeptide is weakly hydrolyzed and resistant to intestinal peptidases, allowing it to maintain biological activity when taken orally. However, most published research used injectable administration (10 mg daily intramuscular for 10 days), which ensures more predictable systemic bioavailability.

Livagen was originally isolated from bovine liver tissue, and its hepatoprotective effects have been extensively studied. It normalizes immune and antioxidant status in the liver, restores liver function during hepatitis and cirrhosis, enhances hepatocyte protein synthesis, and provides immunoprotective effects. Research on the polypeptide liver complex and KEDA tetrapeptide showed maximal hepatoprotective effects in aging models, with normalization of liver enzyme parameters and reduced inflammatory markers.